Augmentation of Human Immunodeficiency Virus Type 1 Neutralizing Antibody by Priming with gpl60 Recombinant Vaccinia and Boosting with rgpl60 in Vaccinia-Naive Adults

Twelve vaccinia-naive volunteers were inoculated with recombinant vaccinia virus expressing the human immunodeficiency virus type 1 (HIV-1) strain IIIB (HIV-$1_{IIIB}$) envelope glycoprotein gpl60 and subsequently immunized with 640 µg of recombinant (r) gpl60 protein produced in baculovirus. After...

Full description

Saved in:
Bibliographic Details
Published in:The Journal of infectious diseases 1993-03, Vol.167 (3), p.533-537
Main Authors: Graham, Barney S., Matthews, Thomas J., Belshe, Robert B., Clements, Mary Lou, Dolin, Raphael, Wright, Peter F., Gorse, Geoffrey J., Schwartz, David H., Keefer, Michael C., Bolognesi, Dani P., Corey, Lawrence, Stablein, Donald M., Esterlitz, Joy R., Hu, Shiu-Lok, Smith, Gale E., Fast, Patricia E., Koff, Wayne C.
Format: Article
Language:English
Subjects:
Antibodies
HIV
HIV 1
Immune response
Major Articles
Neutralizing antibodies
Secondary immunization
Vaccination
Vaccinia
Viruses
Volunteerism
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Twelve vaccinia-naive volunteers were inoculated with recombinant vaccinia virus expressing the human immunodeficiency virus type 1 (HIV-1) strain IIIB (HIV-$1_{IIIB}$) envelope glycoprotein gpl60 and subsequently immunized with 640 µg of recombinant (r) gpl60 protein produced in baculovirus. After booster immunization with rgpl60, the sera of all vaccinees showed strong antibody responses detected by Western blot and ELISA; 8 had neutralizing activity and 5 had fusion inhibition activity against the homologous strain; 5 blocked binding of CD4 cells to gpl20. Cross-reactive neutralization of HIV-$1_{MN}$was detected in 3 of 8 sera that neutralized HIV-$1_{IIIB}$. The combination of live recombinant vaccinia followed by subunit booster immunization was more immunogenic than either product alone and represents a promising approach for HIV-1 immunoprophylaxis. Further definition of recombinant vaccinia safety and augmentation of immune responses to geographically prevalent HIV-1 strains will be necessary before expanding clinical trials to high-risk groups.
ISSN:0022-1899